BR112017019075A2 - anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses - Google Patents
anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico dessesInfo
- Publication number
- BR112017019075A2 BR112017019075A2 BR112017019075-3A BR112017019075A BR112017019075A2 BR 112017019075 A2 BR112017019075 A2 BR 112017019075A2 BR 112017019075 A BR112017019075 A BR 112017019075A BR 112017019075 A2 BR112017019075 A2 BR 112017019075A2
- Authority
- BR
- Brazil
- Prior art keywords
- hard
- antigen binding
- binding fragment
- pharmaceutical use
- antibody
- Prior art date
Links
- 102000008108 Osteoprotegerin Human genes 0.000 title 1
- 108010035042 Osteoprotegerin Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000058171 human SOST Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a um anticorpo humanizado e um anticorpo quimérico que se ligam especificamente à esclerostina humana. os anticorpos são usados para tratar uma doença relacionada ao metabolismo ósseo humano tal como a osteoporose (op).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510112924.5 | 2015-03-13 | ||
CN201510112924 | 2015-03-13 | ||
PCT/CN2016/073857 WO2016145961A1 (zh) | 2015-03-13 | 2016-02-16 | 抗硬骨素抗体、其抗原结合片段及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017019075A2 true BR112017019075A2 (pt) | 2018-04-17 |
Family
ID=56919707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017019075-3A BR112017019075A2 (pt) | 2015-03-13 | 2016-02-16 | anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses |
Country Status (20)
Country | Link |
---|---|
US (1) | US10449250B2 (pt) |
EP (2) | EP3782641A1 (pt) |
JP (1) | JP6755513B2 (pt) |
KR (1) | KR102584953B1 (pt) |
CN (2) | CN106661104B (pt) |
AU (1) | AU2016232897B2 (pt) |
BR (1) | BR112017019075A2 (pt) |
CA (1) | CA2978976C (pt) |
DK (1) | DK3269735T3 (pt) |
ES (1) | ES2835923T3 (pt) |
HR (1) | HRP20201862T1 (pt) |
HU (1) | HUE052528T2 (pt) |
LT (1) | LT3269735T (pt) |
MX (1) | MX2017011480A (pt) |
PT (1) | PT3269735T (pt) |
RS (1) | RS61158B1 (pt) |
RU (1) | RU2716101C2 (pt) |
SI (1) | SI3269735T1 (pt) |
TW (2) | TWI730954B (pt) |
WO (1) | WO2016145961A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109952093B (zh) | 2017-07-27 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 一种sost抗体药物组合物及其用途 |
CN108101984B (zh) * | 2017-12-18 | 2019-10-15 | 中国人民解放军总医院 | 骨硬化蛋白单链抗体的制备方法和用途 |
JP7120531B2 (ja) * | 2018-02-12 | 2022-08-17 | アプタキュア セラピューティクス リミテッド | スクレロスチンに対するアプタマー及びその使用 |
CN113913463B (zh) * | 2021-09-19 | 2023-08-18 | 郭保生 | 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用 |
AU2022401939A1 (en) | 2021-11-30 | 2024-05-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-sost antibody pharmaceutical composition and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2586401T3 (es) * | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
RU2472526C2 (ru) * | 2006-12-26 | 2013-01-20 | Сентро Де Инмунология Молекулар | Фармацевтическая композиция, содержащая анти-cd6 моноклональное антитело, пригодная для диагностики и лечения ревматоидного артрита |
DK2131860T3 (da) * | 2007-03-20 | 2014-01-13 | Lilly Co Eli | Anti-sclerostin-antistoffer |
AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
CA2707400A1 (en) * | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
AR088513A1 (es) | 2011-10-24 | 2014-06-18 | Abbvie Inc | Inmunoenlazantes dirigidos contra esclerostina |
SG11201403718YA (en) * | 2011-12-28 | 2014-07-30 | Amgen Inc | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
-
2016
- 2016-02-16 US US15/556,488 patent/US10449250B2/en active Active
- 2016-02-16 AU AU2016232897A patent/AU2016232897B2/en active Active
- 2016-02-16 EP EP20197476.3A patent/EP3782641A1/en active Pending
- 2016-02-16 HU HUE16764142A patent/HUE052528T2/hu unknown
- 2016-02-16 ES ES16764142T patent/ES2835923T3/es active Active
- 2016-02-16 WO PCT/CN2016/073857 patent/WO2016145961A1/zh active Application Filing
- 2016-02-16 PT PT167641422T patent/PT3269735T/pt unknown
- 2016-02-16 EP EP16764142.2A patent/EP3269735B1/en active Active
- 2016-02-16 CN CN201680001851.5A patent/CN106661104B/zh active Active
- 2016-02-16 RU RU2017132924A patent/RU2716101C2/ru active
- 2016-02-16 CA CA2978976A patent/CA2978976C/en active Active
- 2016-02-16 CN CN201910168894.8A patent/CN111196849B/zh active Active
- 2016-02-16 MX MX2017011480A patent/MX2017011480A/es unknown
- 2016-02-16 RS RS20201482A patent/RS61158B1/sr unknown
- 2016-02-16 BR BR112017019075-3A patent/BR112017019075A2/pt active Search and Examination
- 2016-02-16 JP JP2017546934A patent/JP6755513B2/ja active Active
- 2016-02-16 LT LTEP16764142.2T patent/LT3269735T/lt unknown
- 2016-02-16 DK DK16764142.2T patent/DK3269735T3/da active
- 2016-02-16 KR KR1020177027816A patent/KR102584953B1/ko active IP Right Grant
- 2016-02-16 SI SI201630983T patent/SI3269735T1/sl unknown
- 2016-03-02 TW TW105106269A patent/TWI730954B/zh active
- 2016-03-02 TW TW110117739A patent/TWI790617B/zh active
-
2020
- 2020-11-23 HR HRP20201862TT patent/HRP20201862T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
ECSP17054182A (es) | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 | |
BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
BR112018006251A2 (pt) | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
PE20181013A1 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
BR112018000475A2 (pt) | construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3 | |
BR112017010094A2 (pt) | anticorpos compreendendo regiões constantes de cadeias pesadas modificadas | |
BR112013028779B8 (pt) | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição | |
BR112016022910A2 (pt) | anticorpos contra her2 biespecíficos | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
UA117364C2 (uk) | Похідні аматоксину | |
BR112017019075A2 (pt) | anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
BR112017012954A2 (pt) | composições e métodos para anticorpos que têm como alvo a bmp6 | |
CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
CL2017002705A1 (es) | Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] |